Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8719464 | 0.80 | MAPK1 (0.38) | MAPK1MEN1KMT2A | |
| SCHEMBL15030921 | 0.76 | — | — | |
| SCHEMBL846707 | 0.76 | — | — | |
| SCHEMBL13676327 | 0.76 | — | — | |
| SCHEMBL17848550 | 0.73 | MAPK1 (0.33) | MAPK1POLB | |
| SCHEMBL6018054 | 0.72 | MAPK1 (0.81) | MAPK1MEN1KMT2A | |
| SCHEMBL20906278 | 0.72 | MAPK1 (0.81) | MAPK1MEN1KMT2A | |
| SCHEMBL113383 | 0.72 | MAPK1 (0.81) | MAPK1MEN1KMT2A | |
| SCHEMBL113382 | 0.72 | MAPK1 (0.81) | MAPK1MEN1KMT2A | |
| SCHEMBL14410773 | 0.71 | LMNA (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9969742-B2 | Imidazotriazinone compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170327502-A1 | IMIDAZOTRIAZINONE COMPOUNDS | IRONWOOD PHARMACEUTICALS INC (US) | 2017-11-16 | — | — | US | disclosed |
| US-9725453-B2 | Imidazotriazinone compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-9725453-B2 | Imidazotriazinone compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20170152265-A1 | IMIDAZOTRIAZINONE COMPOUNDS | IRONWOOD PHARMACEUTICALS INC (US) | 2017-06-01 | — | — | US | disclosed |
| US-9540380-B2 | Imidazotriazinone compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-9265767-B2 | 1,2-disubstituted heterocyclic compounds | FORUM PHARMACEUTICALS INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20150344467-A1 | 5- AND 6-MEMBERED HETEROCYCLIC COMPOUNDS | FMR LLC | 2015-12-03 | — | — | US | disclosed |
| US-20150274706-A1 | 1,2-DISUBSTITUTED HETEROCYCLIC COMPOUNDS | FMR LLC | 2015-10-01 | — | — | US | disclosed |
| US-20150191476-A1 | Imidazotriazinone Compounds | FORUM PHARMACEUTICALS INC. | 2015-07-09 | — | — | US | disclosed |
| US-20120232265-A1 | 1,2-Disubstituted Heterocyclic Compounds | ENVIVO PHARMACEUTICALS, INC. | 2012-09-13 | — | — | US | disclosed |
| US-20120157458-A1 | IMIDAZOTRIAZINONE COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. | 2012-06-21 | — | — | US | disclosed |
| US-8071595-B2 | 1,2-disubstituted heterocyclic compounds | ENVIVO PHARMACEUTICALS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-20110224204-A1 | DI-SUBSTITUTED PHENYL COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. | 2011-09-15 | — | — | US | disclosed |
| US-20110224204-A1 | DI-SUBSTITUTED PHENYL COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. | 2011-09-15 | — | — | US | disclosed |
| US-20110183976-A1 | 5- AND 6-MEMBERED HETEROCYCLIC COMPOUNDS | FMR LLC | 2011-07-28 | — | — | US | disclosed |
| US-20100137317-A1 | 1,2-Disubstituted Heterocyclic Compounds | ENVIVO PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20070275964-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER, INC. | 2007-11-29 | — | — | US | disclosed |
| US-7268133-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER, INC. PATENT DEPARTMENT (US) | 2007-09-11 | — | — | US | disclosed |
| US-20040214837-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. | 2004-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232265-A1 | 1,2-Disubstituted Heterocyclic Compounds | PDE12, PDE7A, PDE10A | MAPK1 1096/4885MEN1 2898/4885KMT2A 2279/4885 |
| US-20150344467-A1 | 5- AND 6-MEMBERED HETEROCYCLIC COMPOUNDS | PDE7A, ACHE, PDE5A | MAPK1 2219/4885MEN1 3552/4885KMT2A 2855/4885 |
| US-20150274706-A1 | 1,2-DISUBSTITUTED HETEROCYCLIC COMPOUNDS | PDE12, PDE7A, PDE10A | MAPK1 1096/4885MEN1 2898/4885KMT2A 2279/4885 |
| US-20040214837-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | MAPK1 1959/4885MEN1 4394/4885KMT2A 3816/4885 |
| US-20170152265-A1 | IMIDAZOTRIAZINONE COMPOUNDS | PDE9A, PDE4A, PDE12 | MAPK1 2805/4885MEN1 2942/4885KMT2A 1812/4885 |
| US-20110224204-A1 | DI-SUBSTITUTED PHENYL COMPOUNDS | PDE10A, PDE1A, PDE12 | MAPK1 1615/4885MEN1 4177/4885KMT2A 2228/4885 |
| US-20170327502-A1 | IMIDAZOTRIAZINONE COMPOUNDS | PDE9A, PDE12, PDE4A | MAPK1 1697/4885MEN1 2891/4885KMT2A 1451/4885 |
| US-20150191476-A1 | Imidazotriazinone Compounds | PDE9A, PDE12, PDE4A | MAPK1 1697/4885MEN1 2891/4885KMT2A 1451/4885 |
| US-20110183976-A1 | 5- AND 6-MEMBERED HETEROCYCLIC COMPOUNDS | ACHE, PDE7A, PDE5A | MAPK1 2193/4885MEN1 3571/4885KMT2A 2900/4885 |
| US-20120157458-A1 | IMIDAZOTRIAZINONE COMPOUNDS | PDE9A, PDE4A, PDE12 | MAPK1 2805/4885MEN1 2942/4885KMT2A 1812/4885 |
| US-20070275964-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, GPR18 | MAPK1 2174/4885MEN1 4519/4885KMT2A 3785/4885 |
| US-20100137317-A1 | 1,2-Disubstituted Heterocyclic Compounds | PDE12, PDE7A, PDE10A | MAPK1 1096/4885MEN1 2898/4885KMT2A 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.